MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.8 USD | -0.34% |
|
-1.17% | +18.19% |
| 02:36pm | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
| 13/05 | Merck: phase 3 trial in melanoma halted | CF |
ETFs positioned on Merck & Co., Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 756 M€ | +0.23% | - | |
| 0.08% | 23 M€ | +12.29% | - | |
| 0.08% | 8 M€ | +0.60% | - | |
| 0.06% | 6 M€ | -4.26% | - | |
| 0.05% | 11 M€ | +1.95% | - | |
| 0.03% | 15 M€ | -1.62% | - | |
| 0.01% | 224 M€ | +3.73% | - | |
| 0.01% | 26 M€ | +0.30% | - | |
| 0.01% | 24 M€ | +0.14% | - | |
| 0.03% | 34 M€ | +3.48% | - | |
| 21.12% | 129 M€ | +6.44% | - | |
| 89.70% | 67 M€ | +1.85% | - |
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.3
USD
Average target price
141.6
USD
Spread / Average Target
+9.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.19% | 327B | |
| +30.79% | 682B | |
| +30.35% | 586B | |
| -3.45% | 364B | |
| +4.11% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.04% | 165B | |
| -1.50% | 161B |
- Stock Market
- Equities
- MRK Stock
- Funds and ETFs Merck & Co., Inc.
